Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.

Dr. Shiri Shulman from Assuta discusses the importance of continuity in treatment during wartime and innovative therapies ...

To date, Vabysmo is approved in more than 100 countries for DME and wet, or neovascular, age-related macular degeneration ...

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...

Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic retinopathy, diabetic macular edema and age-related macular degeneration. The ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

including severe retinal vasculitis, associated with faricimab injections used to treat eye conditions including age-related macular degeneration and diabetic macular edema. Faricimab is a ...

a clinical-stage biopharmaceutical company, focuses on developing sustained-release therapeutics for retinal diseases using its proprietary Durasert E™ technology ... The company highlighted strong ...

Calcium channel blocker (CCB)-related edema is quite common in clinical practice and can effectively deter a clinician from continued prescription of these drugs. Its etiology relates to a ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...